Rocket Pharmaceuticals Files 8-K with Officer/Director Changes
Ticker: RCKTW · Form: 8-K · Filed: Mar 29, 2024 · CIK: 1281895
| Field | Detail |
|---|---|
| Company | Rocket Pharmaceuticals, Inc. (RCKTW) |
| Form Type | 8-K |
| Filed Date | Mar 29, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01, $485,000, $2,500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes
TL;DR
Rocket Pharma 8-K: Board shakeup and comp changes filed 3/29, effective 3/25.
AI Summary
Rocket Pharmaceuticals, Inc. filed an 8-K on March 29, 2024, reporting changes effective March 25, 2024. The filing indicates a departure of directors or certain officers, the election of new directors, and updates to compensatory arrangements for certain officers. It also includes financial statements and exhibits.
Why It Matters
Changes in a company's board of directors and executive compensation can signal shifts in strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in directors and officers, especially without detailed explanations in the initial filing, can introduce uncertainty about the company's direction.
Key Players & Entities
- Rocket Pharmaceuticals, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- March 25, 2024 (date) — Earliest event reported
- March 29, 2024 (date) — Date of report
FAQ
What specific changes were made regarding directors or officers?
The filing indicates a departure of directors or certain officers, the election of directors, and the appointment of certain officers, but the specific names and details are not provided in this summary section of the 8-K.
What is the effective date of the reported changes?
The earliest event reported is dated March 25, 2024.
What other items are included in this 8-K filing?
In addition to changes in directors and officers, the filing also includes information on compensatory arrangements of certain officers, and financial statements and exhibits.
What is Rocket Pharmaceuticals, Inc.'s former name?
The former company name was Inotek Pharmaceuticals Corp, with a date of name change on February 26, 2004.
Where is Rocket Pharmaceuticals, Inc. headquartered?
The principal executive offices are located at 9 Cedarbrook Drive, Cranbury, NJ 08512.
Filing Stats: 1,033 words · 4 min read · ~3 pages · Grade level 11.2 · Accepted 2024-03-29 17:17:46
Key Financial Figures
- $0.01 — nge on which registered Common stock, $0.01 par value RCKT The Nasdaq Global Ma
- $485,000 — led to receive an annual base salary of $485,000 and a target annual bonus of 45% of suc
- $2,500,000 — ity compensation equal to approximately $2,500,000, one-half of which will be in the form
Filing Documents
- ef20025500_8k.htm (8-K) — 34KB
- ef20025500_ex99-1.htm (EX-99.1) — 18KB
- image00001.jpg (GRAPHIC) — 4KB
- 0001140361-24-016666.txt ( ) — 198KB
- rckt-20240325.xsd (EX-101.SCH) — 4KB
- rckt-20240325_lab.xml (EX-101.LAB) — 21KB
- rckt-20240325_pre.xml (EX-101.PRE) — 16KB
- ef20025500_8k_htm.xml (XML) — 4KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 25, 2024, Aaron Ondrey was appointed by Rocket Pharmaceuticals, Inc. (the "Company") as the Company's Chief Financial Officer and Principal Financial Officer. Mr. Ondrey, age 48, most recently served as the Chief Financial Officer and principal and financial accounting officer of Mirati Therapeutics, Inc. ("Mirati"), a publicly traded commercial-stage oncology company (acquired by Bristol-Myers Squibb Company in January 2024), a position he held from November 2023 through January 2024, after previously serving as Interim Chief Financial Officer from August 2023 through November 2023. Mr. Ondrey had previously served as the Senior Vice President, Financial Planning and Analysis for Mirati since July 2022. Prior to his time at Mirati, Mr. Ondrey served as Vice President, Finance of Arena Pharmaceuticals, Inc., a publicly traded biotechnology company (acquired by Pfizer Inc. in March 2022) from January 2020 until July 2022. From December 2018 to January 2020, Mr. Ondrey served as Head of Global Commercial Finance at Alexion Pharmaceuticals, Inc., a publicly traded biotechnology company (acquired by AstraZeneca in July 2021). From March 2010 to November 2018, Mr. Ondrey served in various finance roles of increasing responsibility, most recently as Executive Director, Commercial Finance and Business Planning, at Regeneron Pharmaceuticals, Inc., a publicly traded biotechnology company. Mr. Ondrey received his Bachelor of Science in Business Administration and Finance from Case Western Reserve University. On March 25, 2024, the Company and Mr. Ondrey entered into an executive employment agreement (the "Executive Employment Agreement") with an unspecified term, pursuant to which he is initially entitled to receive an annual base salary of $485,000 and a target annual bonus of 45% of such salary. In conne
Financial Statements and Exhibits
Financial Statements and Exhibits. Exhibits. 99.1 Press Release of Rocket Pharmaceuticals, Inc. dated March 26, 2024.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Rocket Pharmaceuticals, Inc. Date: March 29, 2024 By: /s/ Martin Wilson Martin Wilson General Counsel and Chief Corporate Officer, SVP